PepGen (PEPG) Income from Continuing Operations (2021 - 2026)
PepGen (PEPG) posted Income from Continuing Operations of 17763000.0 for Q1 2026, up 2.89% sequentially from 18291000.0 in Q4 2025, and up 41.19% YoY from 12581274.5 in Q1 2025.
Powered by 
Analysis
PepGen (PEPG) Income from Continuing Operations (2021 - 2026) Analysis & Trends
PepGen has reported Income from Continuing Operations for 6 years, with the latest figure at 17763000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 41.19% year-over-year to 17763000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77167000.0 (up 24.92% YoY) and the FY2025 annual result came in at 89655000.0, changed 0.36% from the prior year.
- Income from Continuing Operations improved to 17763000.0 in Q1 2026 per PEPG's latest filing, from 18291000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16319000.0 in Q1 2023 and troughed at 46313000.0 in Q4 2022.
- A 5-year average of 22176529.41 and a median of 19422000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 4709.24% in 2022, then jumped 58.06% in 2023.
- Over 5 years, Income from Continuing Operations stood at 46313000.0 in 2022, then surged by 58.06% to 19422000.0 in 2023, then decreased by 17.7% to 22859000.0 in 2024, then grew by 19.98% to 18291000.0 in 2025, then gained by 2.89% to 17763000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 17763000.0, 18291000.0, and 18026000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | -17.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.81 Mn |
| Mar 31, 2026 | -17.76 Mn |
| Dec 31, 2025 | -18.29 Mn |
| Sep 30, 2025 | -18.03 Mn |
| Jun 30, 2025 | -23.09 Mn |
| Mar 31, 2025 | -30.20 Mn |
| Dec 31, 2024 | -22.86 Mn |
| Sep 30, 2024 | -21.38 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Mar 31, 2024 | -18.02 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Sep 30, 2023 | -23.29 Mn |
| Jun 30, 2023 | -19.52 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -46.31 Mn |
| Sep 30, 2022 | -18.61 Mn |
| Jun 30, 2022 | -17.32 Mn |
| Mar 31, 2022 | -18.25 Mn |
| Dec 31, 2021 | -7.14 Mn |
| Sep 30, 2021 | -8.11 Mn |